First FDA-Approved RSV Vaccine: Which Pharmaceutical Companies Are Entering the $10 Billion Market?

2023-05-09 16:53:00

© Foto: Unsplash

It is a medical milestone: The first RSV vaccine was approved by the FDA last week. Which pharmaceutical companies are now entering the $10 billion market!

More than 60 years after its discovery, there is finally a vaccine against respiratory syncytial virus (RSV). The US Food and Drug Administration (FDA) approved GlaxoSmithKline’s (GSK) Arexvy vaccine last Wednesday. The vaccine could be commercially available in the United States in just a few weeks.

RSV is a potentially life-threatening respiratory infection that primarily affects young children and older adults. “Older adults, especially those with underlying medical conditions such as heart or lung disease or a compromised immune system, are at high risk of developing RSV,” quoted CNN dr Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, in a statement.

Four more RSV vaccines are slated to hit the market later this year. Analysts predict the vaccine market could be worth $10 billion by 2032.

GSK expects proceeds of up to $3.7 billion from the Arexvy sale. Other Big Pharma players also want a piece of the pie. Next up is Pfizer’s RSV vaccine, which is expected to receive FDA approval later this month. But AstraZeneca, Sanofi and Moderna also have vaccines in the works.

GSK and Pfizer’s RSV vaccines are both tailored for people over the age of 60, as is Moderna’s, which has not yet been submitted for FDA approval.

Bavarian Nordic also plans to present the results of a phase 3 study of its RSV vaccine for older adults later this year. Paul Chaplin, President and CEO of Bavarian Nordic, comments: “We have waited for decades for a safe, effective RSV vaccine and there have been numerous attempts that have failed,” said Chaplin. According to Chaplin, there is a saying in Britain that if you wait a long time for a bus, then four will come at once. The race for an RSV vaccine is a bit like that.

US tech stocks with 200 percent return potential! Our stock market expert Lars Wißler has put together five top picks that have had to suffer extremely and now have massive potential for recovery new free analysis researched for you.

Autorin: Gina Moesing, wallstreet:online central editorial office

Free Report: Fallen Big Techs – Here now up to 200% are waving!

Market Expert Is Convinced These Big Tech Stocks Have Fallen Too Far and Are Coming Back!

Click here